In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients

Journal of Chemotherapy

Volumn 10, Issue 3, 1998, Pages 208-214

  Mokaddas, E ^a   Rotimi, V O ^a   Sanyal, S C ^a,b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b IBN SINA HOSPITAL   (Kuwait)

Author keywords

Antibiotic susceptibility; Burn patients; Cephalosporins; Gram negative bacteria; Imipenem; Piperacillin tazobactam

Indexed keywords

AMIKACIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BURN INFECTION; ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; NONHUMAN; PSEUDOMONAS;

EID: 0031815154     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.3.208     Document Type: Article

References (18)

1. Wurtz R, Karajovic M, Dacumos E, Hanumandass M. Nosocomial infections in a burn intensive care unit. Burns 1995; 21: 18-184.
2. Manson WL, Pernot PC, Fidler V, Sauer EW, Klassen HJ. Colonization of burns and duration of hospital stay of severely burned patients. J Hosp Infect 1992; 22: 55-60.
3. Donati L, Scamazzo F, Generous M, Magiland A, Stankov B, Fraschini F. Infection and antibiotic therapy in 4000 burned patients treated in Milan, Italy between 1976 and 1988. Burns 1993; 19: 345-48.
4. Moellering RC Jr. The battle against betalactamases. J Antimicrob Chemother 1993; 31 (suppl A): 1-8.
5. Sanders CC, Sanders WE. Microbial resistance to newer generation beta-lactam antibiotics; clinical and laboratory implications. J Infect Dis 1985; 151: 399-406.
6. Philippon A, Labia R, Jacoby G. Extended. Spectrum beta-lactamases. Antimicrob Agents Chemother 1989; 33: 1131-1136.
7. Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. Arch Intern Med 1991; 151: 886-895.
8. Offenstadt G, Thierry V, Danielle L, Bertrand G. Piperacillin/tazobactam treatment of serious infections in an intensive care unit. Complications Surg 1993; 12 (suppl A): 65-69.
9. Eliopoulos GM, Klimm K, Fevrazo MJ, Jacoby GA, Moellering RC. Comparative in vitro activity of piperacillin combined with beta-lactamase inhibitor tazobactam (YTR830). Diagn Microbiol Infect Dis 1989; 12: 481-488.
10. Higashitani F, Hyodo A, Ishida N. Inhibition of beta-lactamasese by tazobactam and in vitro antibacterial activity of tazobactam combined with piperacillin. Antimicrob Agents Chemother 1990; 25: 567-574.
11. National Committee for Clinical Laboratory Standards. Antimicrobial disk susceptibility tests. Approved standards. M2-15 NCCLS, Villanova, PA, 1993.
12. Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, Gerlach EH. Piperacillin/tazobactam (YTR830) combination: comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteriodes fragilis group strains. Diagn Microbiol Infect Dis 1989; 12: 489-494.
13. Fuchs PC, Barry AL. In vitro activity of piperacillin/tazobactam: a review. Complications Surg 1993; 12 (suppl. A): 22-27.
14. Acar JF, Goldstein FW, Kitzis MD. Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993; 31 (suppl. A): 23-28.
15. Jacobs MR, Aronoff SC, Johenning S, Yamabe S. Comparative activities of beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended spectrum penicillin against ticarcillin-resistant Enterobacteriaceae and Pseudomonas. J Antimicrob Chemother 1986; 18: 177-184.
16. Garau G. Beta-lactamases: current situation and clinical importance. Intensive Care Med 1994; 20 (suppl. 3): 15-19.
17. Livermore DM. Evolution of beta-lactamase inhibitors. Intensive Care Med 1994; 20 (suppl.3): 10-13.
18. Grimm H. A multicentric in vitro evaluation of piperacillin/tazobactam in Germany. Eur J Surg 1994; (suppl 573): 25-29.